BioSpace News Archive

Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Thursday, Feb. 16, 2023 to discuss the company’s fourth quarter and year-end 2022 financial results.

Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023.

Wave Life Sciences Ltd. announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the SVB Securities Global Biopharma Conference at 10:00 a.m. ET on Thursday, February, 16, 2023.

Personalis, Inc., a leader in advanced genomics for precision oncology, announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023.

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2022 after the market closes on Tuesday, February 28, 2023.

Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free inactivated seasonal influenza vaccine quadrivalent (IIV4) candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.

BriaCell Therapeutics Corp. is pleased to announce the results of its annual general and special meeting of shareholders of the Company for the year ended July 31, 2022 held on February 9, 2023.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 16, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

Agilent Technologies Inc. (NYSE: A) today announced the release of new NovoExpress software that introduces integrated compliance tools for NovoCyte flow cytometer systems.

CytoRecovery, Inc., a leader in marker free technologies for the enrichment, sorting, and recovery of live cells, announced today that the National Science Foundation (NSF) has approved its application to receive a Phase II SBIR Research Grant.